Urolithin A and Its Effects on Attention and Sleep Timing in Healthcare Workers After Night Shifts

November 13, 2026 updated by: Liangkai Chen

Effects of Urolithin A on Attention and Circadian Rhythm of Sleep in Healthcare Workers After Night Shifts: An Interventional Study

This pilot study will examine whether taking urolithin A helps healthcare workers stay focused after a night shift. It will also look at changes in fatigue, sleepiness, sleep patterns, and the body's internal clock.

The study plans to enroll 40 physicians and nurses aged 24 to 55 who work scheduled night shifts at Henan Provincial People's Hospital. Participants will be assigned by chance, in equal numbers, to take either 1 gram of urolithin A or a matching placebo capsule by mouth once each morning for five consecutive days, starting the day before the night shift. Participants and the study staff who give out the capsules or assess outcomes will not know which group each participant is in. Participants will follow their usual work schedules.

The main measure is the Stroop interference effect, which is the difference in average response time between correct answers when a color word conflicts with its displayed color and correct answers when they match. The researchers will compare how this measure changes from two days before the night shift to the scheduled follow-up assessments in the two groups.

Participants will also rate their fatigue and sleepiness, wear a wrist device to track sleep, keep a sleep diary, and provide saliva samples to measure melatonin. They will complete tasks that measure alertness and the ability to withhold a response during three MRI scans scheduled before the night shift, on the morning the shift ends, and during recovery. The study will help estimate how much the main measure varies among participants to inform a larger trial.

Study Overview

Detailed Description

This single-center, randomized, double-blind, placebo-controlled pilot trial will be conducted at Henan Provincial People's Hospital. After providing written informed consent and completing baseline assessments, participants will be randomly assigned to a study group. An independent team member who is not involved in recruitment, intervention delivery, or outcome assessment will generate the allocation sequence using SAS version 9.4. Coded study products will be dispensed in enrollment order. Group assignments will be kept confidential until the database is locked, except when emergency unblinding is needed for participant safety.

The day on which the scheduled night shift begins is designated Day 0. Baseline assessments will take place on Day -2. Participants will take their assigned study product each morning from Day -1 through Day 3 and will work their usual scheduled night shift. Computerized Stroop testing will be conducted each morning from Day -2 through Day 4 between 07:00 and 09:00. The final assessment will take place on Day 4, after the dosing period has ended.

Task-based functional MRI will be performed at baseline (Day -2), on the morning the night shift ends (Day 1), and during recovery (Day 3). During each scan, participants will complete an 8-minute Psychomotor Vigilance Task and a 6-minute Go/No-Go task. Stimulus timing and button responses will be recorded and synchronized with image acquisition. Wrist activity recordings will be reviewed alongside sleep diaries to distinguish nighttime sleep from daytime naps and identify periods when the device was removed. Saliva will be collected at scheduled times throughout the observation period, with an additional sample at 03:00 during the night shift. Study staff will record actual sample collection times, review dosing and visit records, and document missed doses, concomitant medication use, and adverse events.

Repeated Stroop interference measurements will be analyzed using a linear mixed-effects model with terms for study group, visit, and their interaction, with adjustment for baseline performance and a participant-level random effect. Estimated between-group differences will be reported with 95% confidence intervals. Exploratory analyses will examine whether changes in task-related brain activity are associated with changes in cognitive performance, fatigue, sleepiness, sleep patterns, and salivary melatonin. Visit completion and adherence data will be used to assess the feasibility of the study procedures for a larger trial.

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Henan
      • Zhengzhou, Henan, China, 450003
        • Henan Provincial People's Hospital
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Haoxiang Xu, Currently pursuing a master's

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

24 years to 55 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Aged 24 to 55 years, inclusive.
  • Physicians or nurses who work scheduled night shifts.
  • No history of neurological or psychiatric disorders.
  • No diagnosed sleep disorder.
  • No contraindications to magnetic resonance imaging (MRI).
  • Right-handed.

Exclusion Criteria:

  • Recent use of sleep aids or psychoactive medications.
  • Severe sleep disruption outside periods of shift work.
  • Gastrointestinal disease that may affect urolithin A absorption.
  • Pregnancy or breastfeeding.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Urolithin A

Participants will take 1 g of urolithin A(StanYouth™️ Urolithin A) in capsule form by mouth once daily between 07:00 and 09:00 for five consecutive days, from the day before the scheduled night shift (Day -1) through Day 3.

Oral urolithin A(StanYouth™️ Urolithin A) capsules at a total daily dose of 1 g. The capsules are taken once each morning between 07:00 and 09:00 for five consecutive days, beginning the day before the scheduled night shift (Day -1) and continuing through Day 3.

Placebo Comparator: Matching Placebo

Participants will take 1 g of matching placebo capsules by mouth once daily between 07:00 and 09:00 for five consecutive days, from Day -1 through Day 3. The placebo capsules contain no urolithin A and match the urolithin A capsules in appearance, color, and packaging.

Oral placebo capsules containing no urolithin A and matching the urolithin A capsules in appearance, color, and packaging. The capsules are taken at a total daily dose of 1 g, once each morning between 07:00 and 09:00 for five consecutive days, from Day -1 through Day 3.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in the Stroop Reaction Time Interference Effect
Time Frame: Baseline (Day -2) and follow-up on Days -1, 0, 1, 2, 3, and 4. Day 0 is the day the scheduled night shift begins.

At each assessment, the Stroop reaction time interference effect is calculated by subtracting the mean reaction time for valid correct responses in congruent trials from the mean reaction time for valid correct responses in incongruent trials. Reaction times are measured in milliseconds. Change from baseline is calculated as the interference effect at each follow-up assessment minus the baseline interference effect. A positive change indicates greater interference than at baseline.

Baseline (Day -2) and follow-up on Days -1, 0, 1, 2, 3, and 4. Day 0 is the day the scheduled night shift begins.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Stroop Reaction Time by Trial Condition,Stroop Response Accuracy by Trial Condition
Time Frame: Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4

Mean reaction time, in milliseconds, for valid correct responses on the computerized Stroop task, reported separately for congruent and incongruent trials.

Percentage of trials with a correct response on the computerized Stroop task, reported separately for congruent and incongruent trials.

Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4
Psychomotor Vigilance Task
Time Frame: Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).

Mean reaction time, in milliseconds, for valid responses. Premature responses and omissions are excluded.

Number of responses with a reaction time of at least 500 milliseconds within the 10-second response window.

Number of slow responses divided by [prespecified denominator], multiplied by 100.

Number of presented targets for which no response is recorded within 10 seconds.

Number of omitted responses divided by[ prespecified denominator], multiplied by 100.

Number of premature responses, defined as button presses during the waiting interval or responses occurring less than 100 milliseconds after target onset.

Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
Go/No-Go Trial
Time Frame: Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).

Mean reaction time, in milliseconds, for correct responses on Go trials. Percentage of presented Go trials with a valid button press within the response window.

Percentage of presented Go trials without a valid button press within the response window.

Percentage of presented No-Go trials with a button press within the response window.

Percentage of presented No-Go trials without a button press within the response window.

Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
Visual Analog Scale for Fatigue Score
Time Frame: Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4.

Participants rate their current fatigue on a 100-mm visual analog scale. Scores range from 0 mm (no fatigue) to 100 mm (extreme fatigue), with higher scores indicating greater fatigue.

Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4.
Karolinska Sleepiness Scale Score
Time Frame: Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4.

Self-rated sleepiness measured on the 9-point Karolinska Sleepiness Scale. Scores range from 1 to 9, with higher scores indicating greater sleepiness.

Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4.
Fatigue Severity Scale Score
Time Frame: Baseline (Day -2) and final follow-up (Day 4).

The 9-item Fatigue Severity Scale assesses the impact of fatigue on daily functioning over the past week. Each item is scored from 1 to 7. Item scores are summed to give a total score ranging from 9 to 63, with higher scores indicating a greater impact of fatigue.

Baseline (Day -2) and final follow-up (Day 4).
Salivary Melatonin Concentration
Time Frame: From 07:00 on Day -2 through the final visit on Day 4. Routine collection times are 07:00, 11:00, 15:00, 19:00, and 23:00, with an additional sample at 03:00 on Day 1.

Melatonin concentration measured in saliva samples collected at scheduled times and reported in [laboratory reporting unit].

From 07:00 on Day -2 through the final visit on Day 4. Routine collection times are 07:00, 11:00, 15:00, 19:00, and 23:00, with an additional sample at 03:00 on Day 1.
Actigraphy-Derived Sleep Parameters
Time Frame: Continuous monitoring from baseline (Day -2) through final follow-up (Day 4).

Total time spent asleep during the recorded sleep episode, estimated from wrist actigraphy and reported in minutes.

Percentage of time in bed spent asleep, estimated from wrist actigraphy. Time from attempting to fall asleep to estimated sleep onset, reported in minutes.

Total time spent awake after initial sleep onset and before final awakening, estimated from wrist actigraphy and reported in minutes.

Number of awakenings detected by wrist actigraphy after initial sleep onset and before final awakening.

Continuous monitoring from baseline (Day -2) through final follow-up (Day 4).
Task-Evoked Brain Activation During the Psychomotor Vigilance Task
Time Frame: Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).

Task-evoked brain activation during the Psychomotor Vigilance Task will be quantified using [metric and unit] for [task contrast] in [prespecified regions or whole-brain analysis].

Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
Task-Evoked Brain Activation During the Go/No-Go Task
Time Frame: Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).

Task-evoked brain activation during the Go/No-Go task will be quantified using [metric and unit] for [task contrast] in [prespecified regions or whole-brain analysis].

Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Jie Wang, PhD, Henan Provincial People's Hospital
  • Study Director: Liangkai Chen, PhD, Huazhong University of Science and Technology
  • Study Director: Yongli Li, PhD, Henan Provincial People's Hospital
  • Study Director: Zhengqian Li, PhD, Peking University Third Hospital
  • Principal Investigator: Haoxiang Xu, Currently pursuing a master's, Henan Provincial People's Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 16, 2026

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

February 1, 2027

Study Registration Dates

First Submitted

November 13, 2026

First Submitted That Met QC Criteria

November 13, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

The scope, timing, and access procedures for sharing individual participant data are under consideration. Any future sharing would be limited to de-identified data made available to qualified researchers or research institutions for scientific purposes, subject to ethics committee requirements and applicable regulations.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe